Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen, Vaia Florou, Yukihiro Toi, Cynthia Cherry, Maida Hafiz, Andrea De Giglio, Mavish Muzaffar, Sandip H. Patel, Shunichi Sugawara, Jarred Burkart, Wungki Park, Rita Chiari, Jun Sugisaka, Gregory A. Otterson, Gilberto de Lima Lopes, Paul R. Walker

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as.

Original languageEnglish (US)
Pages (from-to)1189
Number of pages1
JournalCancer Immunology, Immunotherapy
Volume69
Issue number7
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)'. Together they form a unique fingerprint.

Cite this